Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00121316
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : January 15, 2008
Information provided by:

Brief Summary:

This study is not being conducted in the United States.

Patients who are intolerant of topical corticosteroids (TCS) have either experienced an adverse event resulting from the use of TCS, or require unacceptable levels of exposure to TCS in order to control their AD. This is of particular concern for patients with recurrent flares on delicate skin areas such as the head and neck.

The purpose of this study is to investigate whether pimecrolimus cream 1%, a non-steroidal anti-inflammatory drug, is efficacious in treating mild to moderate head and neck AD in patients who are intolerant of, or dependent on topical corticosteroids.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Pimecrolimus Drug: Placebo Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids
Study Start Date : October 2004
Study Completion Date : July 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Drug: Pimecrolimus
Pimecrolimus Cream 1 %
Other Name: Elidel
Placebo Comparator: 2
Matching vehicle cream (placebo)
Drug: Placebo
Vehicle cream (placebo cream)

Primary Outcome Measures :
  1. The percentage of patients who have a facial Investigator's Global Assessment (IGA) score of 0 or 1 (clear or almost clear)

Secondary Outcome Measures :
  1. Percentage of responders in overall Eczema Area and Severity Index (EASI) score
  2. Percentage of responders in the head and neck EASI score
  3. Percentage of patients achieving at least a 60 % reduction from baseline in the head and neck EASI score
  4. Percentage of patients achieving a score of 0 or 1 for the pruritus score (absent or mild)
  5. Effects on skin atrophy and telangiectasia (spider veins) existing at baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 12 years of age or older
  • Mild to moderate facial AD at screening (facial IGA 2 - 3)
  • Patients intolerant of, or dependent on, topical corticosteroids
  • Diagnosis of atopic dermatitis by the Hanifin and Rajka criteria
  • For female patients, a negative pregnancy test. Women who are pregnant or who are breast-feeding may not be included in the study. Women of child-bearing potential must follow a medically recognized form of contraception.

Exclusion Criteria:

At baseline and throughout the study, patients:

  • Who have AD on greater than 30% of total body surface area in addition to facial eczema
  • Who have concurrent skin disease (e.g. acne) in the study area or active skin infections (active bacterial, viral or fungal infections or infestations, herpes simplex, herpes zoster, chicken pox), or other conditions that may interfere with the evaluation (e.g. generalized erythroderma, Netherton's syndrome)
  • Who are immunocompromised (e.g. Lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history of malignant disease (with the exception of treated basal-cell carcinoma)
  • Who have previously reported poor, no clinical response, or hypersensitivity to topical pimecrolimus cream (Elidel)
  • Who have received phototherapy (e.g. UVA, UVB) or systemic therapy (e.g.immunosuppressants, corticosteroids, cytostatics) known or suspected to have an effect on AD within 4 weeks of Visit 2
  • Who have received investigational drugs within 8 weeks of first application of study drug or planned use of other investigational drugs during participation of this study
  • Who are unlikely to comply with therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00121316

This study is not being conducted in the United States
Novartis Pharma AG, Switzerland
Sponsors and Collaborators
Study Chair: Novartis Pharmaceuticals Novartis Pharmaceuticals

Responsible Party: External Affairs, Novartis Identifier: NCT00121316     History of Changes
Other Study ID Numbers: CASM981C2442
First Posted: July 21, 2005    Key Record Dates
Last Update Posted: January 15, 2008
Last Verified: January 2008

Keywords provided by Novartis:
Atopic dermatitis

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action